drugset / Trial / NCT02176486
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
Timeline
- Start
- 2014-06-09
- Primary completion
- 2017-03-30
- Completion
- 2018-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 0.5 mg | Oral |
| Subject | Ixazomib | Unknown | 2 mg | Oral |
| Subject | Ixazomib | Unknown | 3 mg | Oral |
| Subject | Ixazomib | Unknown | 4 mg | Oral |